Bavarian Nordic A/S (Bavarian Nordic A/S) Tax Provision : $-1 Mil (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Bavarian Nordic A/S Tax Provision?

Bavarian Nordic A/S's tax provision for the three months ended in Dec. 2023 was $0 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2023 was $-1 Mil.

Bavarian Nordic A/S Tax Provision Historical Data

The historical data trend for Bavarian Nordic A/S's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bavarian Nordic A/S Tax Provision Chart

Bavarian Nordic A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

-0.30

-0.73

-1.57

-2.25

-1.13

Bavarian Nordic A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Tax Provision	Get a 7-Day Free Trial															-0.84	-0.02	-0.67	-0.88	0.45

Bavarian Nordic A/S Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1 Mil.

Bavarian Nordic A/S (Bavarian Nordic A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bavarian Nordic A/S (OTCPK:BVNRY) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

BVNKF:USA BAVAc:UK 0DPB:UK BAVA:Denmark BV3:Germany

Address

Philip Heymans Alle 3, Hellerup, DNK, DK-2900

Website

https://www.bavarian-nordic.com

Bavarian Nordic A/S is a biotechnology company focused on the development, manufacturing, and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company has a specific focus on diseases for which the unmet medical need is high. Bavarian generates revenue through government research and development and supply contracts, and from its commercial partnerships. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets.